Xiaobu Ye

10.8k total citations · 3 hit papers
151 papers, 6.8k citations indexed

About

Xiaobu Ye is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaobu Ye has authored 151 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Genetics, 53 papers in Oncology and 37 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaobu Ye's work include Glioma Diagnosis and Treatment (76 papers), Brain Metastases and Treatment (29 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Xiaobu Ye is often cited by papers focused on Glioma Diagnosis and Treatment (76 papers), Brain Metastases and Treatment (29 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Xiaobu Ye collaborates with scholars based in United States, Germany and China. Xiaobu Ye's co-authors include Stuart A. Grossman, Serena Desideri, Steven Piantadosi, Jian Campian, Joy Fisher, Michael Lim, Myrna R. Rosenfeld, Jaishri O. Blakeley, Glenn J. Lesser and Burt Nabors and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Xiaobu Ye

140 papers receiving 6.7k citations

Hit Papers

Immunosuppression in Pati... 2011 2026 2016 2021 2011 2014 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
    2011 413 citations Stuart A. Grossman, Xiaobu Ye et al. Clinical Cancer Research profile →
  2. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
    2014 409 citations Myrna R. Rosenfeld, Xiaobu Ye et al. profile →
  3. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma
    2013 371 citations Kaisorn L. Chaichana, Xiaobu Ye et al. Neuro-Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Xiaobu Ye 2.6k 2.3k 1.4k 1.3k 1.2k 151 6.8k
Mustafa Khasraw 2.3k 0.9× 1.9k 0.8× 1.5k 1.1× 1.7k 1.3× 956 0.8× 194 5.8k
Anna S. Berghoff 3.8k 1.4× 2.2k 0.9× 3.2k 2.3× 1.6k 1.2× 975 0.8× 292 7.4k
Frank S. Lieberman 1.6k 0.6× 2.5k 1.1× 931 0.7× 1.5k 1.1× 854 0.7× 139 5.0k
Chetan Bettegowda 1.7k 0.7× 1.9k 0.8× 1.9k 1.3× 2.3k 1.8× 795 0.6× 306 8.7k
Ian F. Parney 2.6k 1.0× 4.3k 1.9× 2.2k 1.6× 2.1k 1.6× 1.9k 1.6× 198 9.3k
Brian M. Alexander 2.8k 1.1× 2.3k 1.0× 3.1k 2.2× 1.6k 1.2× 502 0.4× 231 7.8k
Dima Suki 1.8k 0.7× 4.0k 1.7× 2.7k 1.9× 1.1k 0.9× 657 0.5× 114 8.6k
Manmeet S. Ahluwalia 3.8k 1.4× 4.6k 2.0× 4.4k 3.1× 1.9k 1.4× 1.4k 1.1× 398 9.6k
Michael D. Chan 1.8k 0.7× 2.4k 1.0× 3.1k 2.2× 1.6k 1.2× 456 0.4× 249 6.8k
Shouhao Zhou 4.5k 1.7× 1.1k 0.5× 1.3k 0.9× 1.1k 0.8× 918 0.7× 162 7.9k

Countries citing papers authored by Xiaobu Ye

Since Specialization
Citations

This map shows the geographic impact of Xiaobu Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobu Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobu Ye more than expected).

Fields of papers citing papers by Xiaobu Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaobu Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobu Ye. The network helps show where Xiaobu Ye may publish in the future.

Co-authorship network of co-authors of Xiaobu Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaobu Ye. A scholar is included among the top collaborators of Xiaobu Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaobu Ye. Xiaobu Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ryu, Samuel, Xiaobu Ye, Jeffrey J. Olson, et al.. (2024). Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy in patients with newly diagnosed glioblastoma. Neuro-Oncology Advances. 6(1). vdae089–vdae089. 4 indexed citations
3.
Schreck, Karisa C., Roy E. Strowd, Burt Nabors, et al.. (2024). Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma. Clinical Cancer Research. 30(10). 2048–2056. 7 indexed citations
4.
Jiang, Kelly, David Kamson, Kristin J. Redmond, et al.. (2024). EPID-29. EPIDEMIOLOGICAL CHARACTERIZATION OF BRAIN METASTASES IN MELANOMA: A LARGE POPULATION BASED-STUDY FROM 2014-2024. Neuro-Oncology. 26(Supplement_8). viii144–viii144. 1 indexed citations
5.
Jiang, Kelly, Tej D. Azad, David Kamson, et al.. (2023). Epidemiology and survival outcomes of synchronous and metachronous brain metastases: a retrospective population-based study. Neurosurgical FOCUS. 55(2). E3–E3. 14 indexed citations
6.
Schiff, David, Ranjit S. Bindra, Jing Li, et al.. (2023). CTNI-41. PHASE II AND PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMAS. Neuro-Oncology. 25(Supplement_5). v84–v84. 3 indexed citations
7.
Romo, Carlos G., Bronwyn Slobogean, Shannon Langmead, et al.. (2022). Natural history study of cutaneous neurofibromas in people with NF1: Research in Progress (P1-1.Virtual). Neurology. 98(18_supplement). 1 indexed citations
8.
Huff, Carol Ann, Anna Ferguson, Lakshmi Rudraraju, et al.. (2021). An Allogeneic Multiple Myeloma GM-CSF–Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission. Clinical Cancer Research. 27(24). 6696–6708. 12 indexed citations
9.
Blakeley, Jaishri O., Stuart A. Grossman, S. Andrew, et al.. (2018). Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research. 25(1). 73–79. 18 indexed citations
10.
Holdhoff, Matthias, Güneş Güner, Fausto J. Rodríguez, et al.. (2016). Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization. Clinical Cancer Research. 23(12). 3150–3157. 52 indexed citations
11.
Blakeley, Jaishri O., Xiaobu Ye, Dan G. Duda, et al.. (2016). Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas. Journal of Clinical Oncology. 34(14). 1669–1675. 86 indexed citations
12.
Maxwell, Russell, Tomás Garzón-Muvdi, Evan J. Lipson, et al.. (2016). BRAF‐V600 mutational status affects recurrence patterns of melanoma brain metastasis. International Journal of Cancer. 140(12). 2716–2727. 24 indexed citations
13.
Pan, Edward, Jeffrey G. Supko, Thomas Kaley, et al.. (2016). Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. Journal of Neuro-Oncology. 130(3). 571–579. 41 indexed citations
14.
Grossman, Rachel, Peter C. Burger, Ethan Soudry, et al.. (2015). MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. Journal of Clinical Neuroscience. 22(12). 1938–1942. 21 indexed citations
15.
Veerakumar, Ashan, Jennifer J. Cheng, Abraham Sunshine, et al.. (2014). Baclofen dosage after traumatic spinal cord injury: A multi-decade retrospective analysis. Clinical Neurology and Neurosurgery. 129. 50–56. 4 indexed citations
16.
Cimino‐Mathews, Ashley, Xiaobu Ye, Alan K. Meeker, Pedram Argani, & Leisha A. Emens. (2013). Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Human Pathology. 44(10). 2055–2063. 101 indexed citations
17.
Chen, Linda, Hugo Guerrero‐Cazares, Xiaobu Ye, et al.. (2013). Increased Subventricular Zone Radiation Dose Correlates With Survival in Glioblastoma Patients After Gross Total Resection. International Journal of Radiation Oncology*Biology*Physics. 86(4). 616–622. 111 indexed citations
18.
Grossman, Stuart A., Xiaobu Ye, Marc C. Chamberlain, et al.. (2009). Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial. Journal of Clinical Oncology. 27(25). 4155–4161. 131 indexed citations
19.
20.
Flume, Patrick A., Charlie Strange, Xiaobu Ye, et al.. (2005). Pneumothorax in Cystic Fibrosis. CHEST Journal. 128(2). 720–728. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mustafa Khasraw Breakdown of academic impact, for papers by Anna S. Berghoff Breakdown of academic impact, for papers by Frank S. Lieberman Breakdown of academic impact, for papers by Chetan Bettegowda Breakdown of academic impact, for papers by Ian F. Parney Breakdown of academic impact, for papers by Brian M. Alexander Breakdown of academic impact, for papers by Dima Suki Breakdown of academic impact, for papers by Manmeet S. Ahluwalia Breakdown of academic impact, for papers by Michael D. Chan Breakdown of academic impact, for papers by Shouhao Zhou
Rankless by CCL
2026